Assembly Biosciences is a biotechnology company developing clinical candidates for the treatment of chronic hepatitis B virus (HBV) infection, an early-stage development program targeting high-recurrence genital herpes and research programs focused on the discovery of novel antivirals to treat viral diseases, including hepatitis delta virus (HDV), herpes simplex virus type 2 and transplant related herpesviruses. Co.'s HBV and HDV programs include: Core Inhibitors, which consist of 3733 and 4334; HBV/HDV Entry Inhibitor, which focuses on an orally bioavailable small molecule approach to inhibit entry of HBV and HDV; and IFNAR Agonist. The ASMB stock yearly return is shown above.
The yearly return on the ASMB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ASMB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|